{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:34Z","timestamp":1790085694401,"version":"4.0.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Checkpoint inhibitor pneumonitis (CIP) is an uncommon but potentially life-threatening immune-related adverse event that may interrupt effective anticancer therapy and require prolonged immunosuppression. Its clinical presentation, radiographic appearance, inflammatory biology, and response to corticosteroids vary substantially, while infection, radiation pneumonitis, tumor progression, pulmonary embolism, and pre-existing interstitial lung disease may produce overlapping findings. Conventional severity grading remains important for communication and triage but does not fully capture this heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review content<\/jats:title>\n                    <jats:p>This narrative review synthesizes clinical, radiographic, immunological, and treatment-response evidence to develop a framework for phenotype-guided CIP management. We conceptualize CIP as a dynamic pulmonary immune syndrome and organize its assessment across four dimensions: clinical severity, radiographic phenotype, inflammatory and immune phenotype, and corticosteroid responsiveness. Emerging evidence involving CD4+ and CD8+ memory and tissue-resident T cells, Th17.1 and Tfh-like programs, pro-inflammatory monocytes and macrophages, cytokine networks, and humoral responses is linked to clinically relevant questions while remaining hypothesis-generating. Three patterns are emphasized: low-inflammatory-burden, steroid-responsive disease; high-risk progressive disease; and persistent immune-activation or steroid-refractory disease. The framework connects these patterns with diagnostic reassessment, multidisciplinary evaluation, corticosteroid treatment, recognition of treatment failure, immunomodulatory escalation, chronic pulmonary follow-up, and individualized immune checkpoint inhibitor rechallenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CIP should not be managed as a single toxicity defined by grade alone. Joint interpretation of clinical trajectory, imaging, inflammatory signals, and corticosteroid response may improve risk stratification and support more proportionate diagnostic and therapeutic decisions. This framework is a clinically grounded heuristic rather than a validated algorithm and requires prospective multicenter evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1961402","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:13:58Z","timestamp":1790082838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From inflammatory phenotypes to clinical decisions: a stratified diagnostic and therapeutic framework for CIP"],"prefix":"10.3389","volume":"17","author":[{"given":"Shanshan","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Yueqing People\u2019s Hospital","place":["Yueqing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenye","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yueqing People\u2019s Hospital","place":["Yueqing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binlong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yueqing People\u2019s Hospital","place":["Yueqing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yueqing People\u2019s Hospital","place":["Yueqing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yueqing People\u2019s Hospital","place":["Yueqing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/nejmoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"190058","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"RadioGraphics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1258","article-title":"Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience","volume":"10","author":"Lin","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.935779","article-title":"Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1202st","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis: an official American Thoracic Society research statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.07.023","article-title":"Immune checkpoint inhibitor-related pneumonitis: from guidelines to the front lines","volume":"63","author":"Karayama","year":"2025","journal-title":"Respir Investig"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.32388\/erjxiq","article-title":"Common terminology criteria for adverse events (CTCAE)","author":"National Cancer","year":"2021"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001298","article-title":"Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis","volume":"43","author":"Larsen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.870842","article-title":"Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1495450","article-title":"Development and validation of a nomogram for differentiating immune checkpoint inhibitor-related pneumonitis from pneumonia in patients undergoing immunochemotherapy: a multicenter, real-world, retrospective study","volume":"16","author":"Duan","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and proinflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00262-025-03983-8","article-title":"Single-cell transcriptome sequencing reveals the immune microenvironment in bronchoalveolar lavage fluid of checkpoint inhibitor-related pneumonitis","volume":"74","author":"Zheng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.818492","article-title":"Comprehensive analysis of the immune microenvironment in checkpoint inhibitor pneumonitis","volume":"12","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03750-z","article-title":"Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case\u2013control study","volume":"148","author":"Kowalski","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00262-025-04053-9","article-title":"Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis","volume":"74","author":"Hazim","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/mcp.0000000000001175","article-title":"Immune checkpoint inhibitor-associated pneumonitis: focus on diagnosis and underlying mechanisms","volume":"31","author":"Khoury","year":"2025","journal-title":"Curr Opin Pulm Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000515","article-title":"Clinical manifestation, risk factors, and immune checkpoint inhibitor rechallenge of checkpoint inhibitor-associated pneumonitis in patients with lung cancer","volume":"47","author":"Li","year":"2024","journal-title":"J Immunother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1527690","article-title":"Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00981-2023","article-title":"Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia","volume":"10","author":"Isobe","year":"2024","journal-title":"ERJ Open Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698832","article-title":"Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/rct.0000000000001643","article-title":"High-resolution CT patterns of anti-PD1 checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"48","author":"Pan","year":"2024","journal-title":"J Comput Assist Tomogr"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1186\/s12885-025-14628-5","article-title":"Imaging features and prognostic significance of immune checkpoint inhibitor-related pneumonitis in NSCLC","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6244","article-title":"A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1607170","article-title":"Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1159\/000543556","article-title":"Characteristics and risk factors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: a retrospective study","volume":"103","author":"Cui","year":"2025","journal-title":"Oncology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111489","article-title":"Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer","volume":"128","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002804","article-title":"Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial","volume":"9","author":"Sierra-Rodero","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pccm.2024.12.001","article-title":"Clinical management of checkpoint inhibitor pneumonitis: focus, challenges, and future directions","volume":"3","author":"Xu","year":"2025","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2026.1730022","article-title":"Metagenomic next-generation sequencing for diagnosis of immune checkpoint inhibitor-associated pneumonitis: a retrospective comparative clinical performance study","volume":"16","author":"Jiang","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00262-024-03902-3","article-title":"Cytokine profile of bronchoalveolar lavage in patients with and without checkpoint inhibitor pneumonitis","volume":"74","author":"Ploch","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2018","journal-title":"Oncoimmunology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa022","article-title":"Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease","volume":"32","author":"Suzuki","year":"2020","journal-title":"Int Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-026-04224-z","article-title":"Bronchoalveolar lavage fluid lymphocytosis in immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2026","journal-title":"BMC Pulm Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030531","article-title":"Memory CD4+ T cells in immunity and autoimmune diseases","volume":"9","author":"Raphael","year":"2020","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2019","journal-title":"Immunol Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06202-2","article-title":"Th17.1 lymphocytes: emerging players in the orchestra of immune-mediated inflammatory diseases","volume":"41","author":"Misra","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B65","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1582714","article-title":"Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis","volume":"12","author":"Mir","year":"2025","journal-title":"Front Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41419-026-08440-7","article-title":"Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy","volume":"17","author":"Li","year":"2026","journal-title":"Cell Death Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101484","article-title":"Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis","volume":"9","author":"Ando","year":"2021","journal-title":"Biomedicines"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11618","article-title":"Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol Lett"},{"key":"B74","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12885-026-15729-5","article-title":"Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients","volume":"26","author":"Tao","year":"2026","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1961402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:13:59Z","timestamp":1790082839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1961402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2026.1961402"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1961402","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1961402"}}